November 28, 2014 4:45 PM ET

Life Sciences Tools and Services

Company Overview of Ajinomoto Althea, Inc.

Company Overview

Ajinomoto Althea, Inc. operates as a contract development and manufacturing organization that provides clinical and commercial product development services. It offers aseptic drug product fill and finish services in the areas of formulation, aseptic vial filling, aseptic syringe filling, lyophilization, release testing, clinical packaging, and stability programs; biologics manufacturing services, such as upstream and downstream process development, and cGMP manufacturing (cGMP protein and DNA plasmid production), as well as a systems that provides pharmaceutical and biotechnology partners with peptides and protein biological products; protein analytics stability testing in the areas of analy...

11040 Roselle Street

San Diego, CA 92121

United States

Founded in 1997





Key Executives for Ajinomoto Althea, Inc.

Chief Executive Officer and President
Co-Founder and Director
Chief Financial Officer and Senior Vice President
Age: 61
Senior Vice President of Operations
Director of Biologics Manufacturing
Compensation as of Fiscal Year 2014.

Ajinomoto Althea, Inc. Key Developments

Ajinomoto Althea Inc. Appoints J. David Enloe Jr. as President and Chief Executive Officer

Ajinomoto Althea Inc. announced the appointment of J. David Enloe Jr. as President and CEO. Mr. Enloe will be responsible for developing strategies to support the company's continued growth. Enloe brings over 20 years of executive management experience most of that in biotechnology, drug development, and GMP manufacturing management. Most recently, he served as the Head of the Viral Therapeutics Business Unit at Lonza AG. Mr. Enloe joined the team effective December 16, 2013. Dr. Hiroshi Shiragami and Dr. Magda Marquet will continue to serve Ajinomoto Althea Inc. as Co-Chairs of the board of directors.

Ajinomoto Althea, Inc. Presents at BioJapan 2013 World Business Forum, Oct-09-2013

Ajinomoto Althea, Inc. Presents at BioJapan 2013 World Business Forum, Oct-09-2013 . Venue: Pacifico Yokohama, Yokohama, Japan.

Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement for Plasmid DNA Production

Althea Technologies, Inc. and Profectus BioSciences Inc. announced the signing of a manufacturing supply agreement for plasmid DNA production. Under the agreement, Althea will provide gram-scale quantities of cGMP (current Good Manufacturing Practice) manufactured plasmid DNA expressing IL-12 to assist Profectus Biosciences' ongoing DNA vaccine development efforts, which are supported by a contract from the National Institutes of Health. IL-12 helps prompt an immune response once the DNA enters a cell, which is part of Profectus Biosciences' technology platform designed to overcome the poor delivery and immunogenicity of many DNA vaccines.

Similar Private Companies By Industry

Company Name Region
Chromocell Corporation United States
MedSites, Inc. United States
Medco Research Institute, L.L.C. United States
ClinDatrix, Inc. United States
ProTrials Research, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ajinomoto Althea, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at